GLPwatch
Papers (10382)
Page 112 of 174, ranked by citation count.
- Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.
- Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
- Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
- Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study.
- Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.
- Novel oral agents in anti-obesity pharmacotherapy: A narrative review.
- Increase in cortisol/ACTH ratio after chronic treatment with liraglutide in patients with type 2 diabetes.
- Liraglutide and cardiovascular outcomes in type 2 diabetes.
- Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.
- Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.
- Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.
- The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.
- How to fight obesity with antidiabetic drugs: targeting gut or kidney?
- Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin.
- Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
- Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells.
- Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- Exenatide-induced granulomatous panniculitis associated with poly(d,l-lactide-co-glycolide).
- The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.
- The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
- Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
- Electrochemical Sensing of the Peptide Drug Exendin-4 Using a Versatile Nucleic Acid Nanostructure.
- Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
- Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.
- Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
- Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
- Anorectic state of obesity medications in the United States. Are leaner times ahead?
- Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
- Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.
- Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
- The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
- Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
- Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway.
- Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy.
- [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver].
- Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.
- Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
- HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
- Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study.
- Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.
- Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
- Incretin receptor agonism during pregnancy: implications for mother and baby.
- Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission.
- Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework.
- Oral semaglutide for the treatment of obesity: a retrospective real-world study.
- Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance.
- The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.
- Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.
- Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.
- Protective effect of liraglutide on experimental testicular ischaemia reperfusion in rats.
- The estrogenic reduction in water intake stimulated by dehydration involves estrogen receptor alpha and a potential role for GLP-1.
- Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.
- Development and characterization of exendin-4 loaded self-nanoemulsifying system and <i>in vitro</i> evaluation on Caco-2 cell line.
- Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.
- Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
- Advances in Drug Treatments for Companion Animal Obesity.
- Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
- The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.